Ernexa Therapeutics Releases Investor Presentation and Fact Sheet

What Happened
Ernexa Therapeutics, Inc. (ERNA) filed a Form 8‑K on September 16, 2026 (Item 7.01) to disclose that it made its corporate fact sheet and an investor presentation available to the public. The materials are attached to the filing as Exhibit 99.1 (Fact Sheet, dated September 16, 2026) and Exhibit 99.2 (Investor Presentation - September 2026) and are incorporated by reference.

Key Details

• Filing date: September 16, 2026; disclosure made under Regulation FD (Item 7.01).
• Exhibits attached: 99.1 (Ernexa Therapeutics Fact Sheet) and 99.2 (Investor Presentation).
• Form 8‑K also lists Interactive XBRL cover page (Exhibit 104).
• The filing is limited to the disclosure of those investor materials; it does not report earnings, executive changes, mergers/acquisitions, or other Item 2.02/5.02 events.

Why It Matters
This 8‑K provides investors direct access to Ernexa’s current corporate overview and investor presentation materials, which may include updates on strategy, product pipeline, and company highlights. Retail investors should review the attached exhibits for details relevant to valuation or upcoming catalysts; because the filing contains only the materials (not new financial statements or executive announcements), follow‑up filings may be needed for formal financial results or material events.